ArticleBMC complementary medicine and therapies2025
Based on network pharmacology and molecular docking technology to explore the pharmacodynamic components and mechanism of Gynostemmae Pentaphylli Herba reversing Cervical intraepithelial neoplasia.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration of Potential Antidepressant Active Ingredients ofJournal of analytical methods in chemistry · 2026Article
- Therapeutic Potential ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate the pharmacodynamic components of Gynostemmae Pentaphylli Herba reversing Cervical intraepithelial neoplasia (CIN) were investigated by network pharmacology, and the mechanism of action was analyzed by molecular docking technology.
methodsThe effective components and targets of Gynostemmae Pentaphylli Herba and the disease target of CIN were searched in TCMSP, Pubchem, Swiss Target Prediction, GenCards, WebGestalt, and STRING. Based on the above data and the Cytoscape software, we mapped the protein-protein interaction (PPI) co-expression network. The mechanism of Gynostemmae Pentaphylli Herba CIN treatment was identified from the enrichment analysis perspective. We performed molecular docking on the AutoDock. Finally, we carried out cell experiments for verification.
resultsEighty-five targets matching the active ingredients of Gynostemmae Pentaphylli Herba, and 2512 CIN-related action targets were obtained. The nodal degree values of five components and the target of Gynostemmae Pentaphylli Herba in the top 5 were IL6, IL1β, TNF, TP53, and PTGS2. There were 52 intersection targets of the effective active ingredient of Gynostemmae Pentaphylli Herba and CIN. The PPI network map suggested that the main active ingredient MOL000098 (Quercetin) had the most targets (40), followed by MOL000351 (Rhamnazin) (17). Gene Ontology (GO) analysis yielded the regulation of transcription from RNA polymerase II promoter, cytoplasm, extracellular space and enzyme binding, zinc ion binding, etc. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway identified 114 signaling pathways. These pathways were mainly enriched in positive regulation of transcription from RNA polymerase II promoter, positive regulation of gene expression, cytoplasm, extracellular space, enzyme binding, zinc ion binding, Pathways in cancer, Fluid shear stress and atherosclerosis, etc. The binding energies of IL6, IL1β, TNF, TP53, and PTGS2 with Quercetin, Rhamnazin, Gypenoside XXVII_qt and Gypenoside XXVIII_qt were all less than -5 kcal·mol
conclusionGynostemmae Pentaphylli Herba may reverse CIN through targeted action of Quercetin, Rhamnazin, and gypenosides, as well as various pathways. Our study preliminarily explored the pharmacodynamic components and mechanism of the reversal of CIN by Gynostemmae Pentaphylli Herba and verified the possible mechanism of action through cell and molecular biology experiments to understand the pharmacological mechanism of Gynostemmae Pentaphylli Herba in CIN and provide data reference for new drugs and clinical trials research, which will be of great significance for clinical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.